Literature DB >> 24714271

Reducing radiation risks during ERCP: less is more.

Thomas J Savides.   

Abstract

Entities:  

Year:  2012        PMID: 24714271      PMCID: PMC3959412     

Source DB:  PubMed          Journal:  Ann Gastroenterol        ISSN: 1108-7471


× No keyword cloud information.
Quality ERCP includes safety as well as efficacy. During ERCP, safety not only refers to immediate risks to the patient such as pancreatitis, bleeding and perforation, but also includes radiation risks to both the patient and the medical providers. There are numerous factors associated with radiation risk, including proper education and use of equipment, shielding of personnel, and procedure performance. The study by Katsinelos and colleagues in this issue of Annals of Gastroenterology prospectively evaluates clinical parameters related to fluoroscopy time during ERCP. The majority of patients were undergoing ERCP for an indication of choledocholithiasis (79%) or malignancy (9%). Nearly all the procedures (99%) were therapeutic in terms of endoscopic sphincterotomy, stone extraction, mechanical lithotripsy, and/or stent placement. Multivariate analysis found that variables significant for increased fluoroscopy time included choledocholithiasis, two or more stones, stone size greater than 10 mm, needle-knife papillotomy, periampullary diverticulum, and mechanical lithotripsy with stent placement [1]. All of these parameters are related to more technically challenging ERCP than one would encounter during removal of a small (<10 mm) stone or placement of a stent for distal biliary obstruction. This study confirms previous studies that more complicated therapeutic ERCP cases require greater fluoroscopy time than less complex procedures [2-5]. Perhaps an even more interesting aspect of this study is that this single experienced endoscopist used an average of only 49 sec of fluoroscopy per case. Nearly all of the cases (99%) required some form of therapy. In contrast, most published research studies related to radiation exposure during ERCP report mean rates of over 300 sec (5 min) [2,3,5-9]. The endoscopist in the current study performed a high volume of cases, more than 350 per year, during the study period. This confirms other studies that have also shown high volume endoscopists (>200 ERCP per year) have significantly shorter fluoroscopy times than endoscopists performing fewer procedures (especially <100 ERCP per year) [10]. Additionally, fluoroscopy time is inversely correlated with endoscopist experience, with a reported decrease in fluoroscopy time of 20% for every ten years of experience [4,10]. A recent 2012 European Society of Disease Endoscopy (ESGE) guideline on radiation protection had several recommendations for reducing radiation exposure during ERCP [11]. These included positioning the patient as far as possible from the x-ray tube, limiting fluoroscopy time, using pulsed fluoroscopy instead of continuous fluoroscopy, selecting the lowest reasonable image quality, collimate the X-ray beam to the smallest practical size, avoid unnecessary magnification, limit taking radiographic still images, and have experienced endoscopists perform more complex cases. One can speculate on why experienced endoscopists might utilize less fluoroscopy time. A large part of this might be awareness of risks of radiation exposure that occurs over time, not to mention concern for their own cumulative radiation exposure. Experienced endoscopists may control the foot peddle for the fluoroscopic imaging (or have a good working relationship with the person who does), and so not have time delay in assessing the image as can occur if a radiologist or radiology technician independently controls the fluoroscopic imaging. They may have greater initial success at cannulation (perhaps using wire-guided techniques) and thus need less fluoroscopic imaging for initial cannulation. They also may be part of regional centers with access to non-ERCP biliary imaging such as MRCP and EUS, which can inform the endoscopist of the expected underlying pathology before the ERCP. Knowing the definite pre-ERCP pathology (i.e. bile duct stone or pancreatic tumor), can then mean less diagnostic fluoroscopy time is required and the fluoroscopy can be used only for what is needed to perform the therapeutic procedure. Over the past decade there has been an increasing emphasis on quality performance in endoscopy, and this includes quality ERCP. Potential metrics for ERCP quality include number of cases per year, percentage of diagnostic versus therapeutic cases, complexity of cases, success of deep biliary cannulation (when relevant), success at removal of bile duct stones (<10 mm), success in relieving distal biliary obstruction, and immediate adverse events (i.e. pancreatitis, bleed, perforation) [12,13]. Perhaps fluoroscopy time should also be included as another ERCP quality indicator, given that there seems to be great variability in the amount of radiation exposure to patients and medical providers based on complexity of procedures as well as endoscopist experience. Hopefully studies such as this by Katsinelos et al will encourage all of us to evaluate factors which influence fluoroscopy times in our units during ERCP, and anticipate challenging cases and consciously limit fluoroscopic imaging to when only absolutely needed.
  13 in total

1.  Radiation doses to patients during ERCP.

Authors:  C J Larkin; A Workman; R E Wright; T C Tham
Journal:  Gastrointest Endosc       Date:  2001-02       Impact factor: 9.427

2.  Radiation exposure during ERCP: effect of a protective shield.

Authors:  M Y Chen; F L Van Swearingen; R Mitchell; D J Ott
Journal:  Gastrointest Endosc       Date:  1996-01       Impact factor: 9.427

3.  Prospective analysis of fluoroscopy duration during ERCP: critical determinants.

Authors:  Edward Kim; Mark McLoughlin; Eric C Lam; Jack Amar; Michael Byrne; Jennifer Telford; Rob Enns
Journal:  Gastrointest Endosc       Date:  2010-07       Impact factor: 9.427

4.  Patient and staff exposure during endoscopic retrograde cholangiopancreatography.

Authors:  N Buls; J Pages; F Mana; M Osteaux
Journal:  Br J Radiol       Date:  2002-05       Impact factor: 3.039

5.  Radiation exposure to patients and personnel during interventional ERCP at a teaching institution.

Authors:  R L Heyd; K K Kopecky; S Sherman; G A Lehman; S M Stockberger
Journal:  Gastrointest Endosc       Date:  1996-09       Impact factor: 9.427

6.  Radiation doses to ERCP patients are significantly lower with experienced endoscopists.

Authors:  Jennifer E Jorgensen; Joel H Rubenstein; Mitchell M Goodsitt; Grace H Elta
Journal:  Gastrointest Endosc       Date:  2010-04-24       Impact factor: 9.427

7.  Patient radiation doses and references levels in interventional radiology.

Authors:  Marco Brambilla; Giuseppe Marano; Marco Dominietto; Antonio Raffaele Cotroneo; Alessandro Carriero
Journal:  Radiol Med       Date:  2004-04       Impact factor: 3.469

8.  Quality indicators, including complications, of ERCP in a community setting: a prospective study.

Authors:  Joshua B Colton; Colleen C Curran
Journal:  Gastrointest Endosc       Date:  2009-05-30       Impact factor: 9.427

9.  Radiation doses to patients from endoscopic retrograde cholangiopancreatography examinations and image quality considerations.

Authors:  I A Tsalafoutas; K D Paraskeva; E N Yakoumakis; A E Vassilaki; P N Maniatis; J A Karagiannis; E D Koulentianos
Journal:  Radiat Prot Dosimetry       Date:  2003       Impact factor: 0.972

10.  A prospective analysis of factors influencing fluoroscopy time during therapeutic ERCP.

Authors:  Panagiotis Katsinelos; Anthi Gatopoulou; Stergios Gkagkalis; Kostas Fasoulas; Athanasios Beltsis; Christos Zavos; Sotiris Terzoudis; Georgia Lazaraki; Grigoris Chatzimavroudis; Ioannis Vasiliadis; Jannis Kountouras
Journal:  Ann Gastroenterol       Date:  2012
View more
  1 in total

1.  Attitudes to radiation safety and cholangiogram interpretation in endoscopic retrograde cholangiopancreatography (ERCP): a UK survey.

Authors:  Keith Siau; George Webster; Mark Wright; Ben Maher; Brian Stedman; Gavin Johnson; Saqib Ahmad; Nadeem Tehami
Journal:  Frontline Gastroenterol       Date:  2020-12-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.